Navigation Links
Minimally Invasive Treatment Offers Hope for Liver Cancer Patients
Date:3/13/2008

In 2007, over 85% of liver cancer treatments performed in interventional

radiology suites used transcatheter chemoembolization, according to

Millennium Research Group

WALTHAM, Mass., March 13 /PRNewswire/ -- Data from Millennium Research Group's (MRG's) US Interventional Radiology (IR) Marketrack(TM) indicates that in 2007, over 85% of liver cancer treatments performed in IR suites used transcatheter chemoembolization, a procedure that delivers chemotherapy agents directly to a tumor through minimally invasive means.

Microsphere particles, including Boston Scientific's Contour SE, Biosphere Medical's Embosphere, and others, were used in 40% of these treatments. Overall, chemoembolization particles generated nearly 20% of total microsphere revenue. As such, chemoembolization procedures are a key segment in the overall embolic particle market, which, in addition to standard microspheres, includes drug-infused microspheres, selective internal radiation therapy (SIRT) spheres, and polyvinyl alcohol (PVA) particles. MRG's US IR Marketrack(TM) service monitors the adoption of embolic particles for liver cancer, uterine fibroids, aneurysms, hemorrhages, and vascular anomalies.

"In chemoembolization, chemotherapy agents are mixed with embolic particles and are delivered through a catheter directly to the tumor, thereby localizing the chemo treatment" says Phil Scrutton, Analyst at MRG. "The particles also embolize the surrounding arteries, blocking blood flow to the cancerous tissue. This slows diffusion of the chemotherapy agents away from the tumor, which increases its effectiveness in targeting the liver tumor, while the embolization also deprives the tumor of oxygen and nutrients."

Liver cancer has historically had a poor prognosis, but the use of embolic particles in conjunction with drugs in chemoembolization, while not a cure, is leading to longer life expectancies for cancer sufferers. These positive clinical outcomes, the availability of improved embolization technologies, and an increasing rate of patient referrals for this treatment are all contributing to embolic particle market growth.

Millennium Research Group will be attending the Society of Interventional Radiology annual meeting in Washington, DC from March 16-19. Come to booth #304 to discover how we can help you meet your needs.

About Interventional Radiology Marketrack(TM)

IR Marketrack(TM) gathers quarterly data from interventional radiology labs throughout the US, including data on PV embolizations, varicose vein treatments, and vascular access procedures. Marketrack(TM) subscribers receive thousands of data points, including usage (units, average selling price, and revenue), procedure, competitor, and device brand information.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Microfabrica Introduces Set of Miniature Building Blocks for Minimally-Invasive Medical Devices
2. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
3. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
4. InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
5. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
6. Masimo Announces Continuous Noninvasive Total Hemoglobin
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Linda, Ca (PRWEB) , ... August 15, 2017 ... ... coffee production and is threatened by various biotic and abiotic factors. During this ... complex evolutionary history of coffee, as well as gain a better understanding of ...
(Date:8/14/2017)... , ... August 14, 2017 , ... ... essential device-to-computer interconnect using USB or PCI Express, announced the release of SYZYGY™, ... is intended to satisfy the need for a compact, low cost, low pin-count, ...
(Date:8/11/2017)... San Antonio, Texas (PRWEB) , ... August 11, 2017 , ... ... launching a rebranding campaign this month that will incorporate important key elements including a ... to thank the community that has supported them, Bill Miller has partnered with the ...
(Date:8/10/2017)... ... August 09, 2017 , ... As a full-service marketing agency, ... customers with the right message. Their effective, cutting-edge inbound marketing strategies are available ... how crucial the agriculture industry is,” said David Phelps, chief marketing officer at ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:5/6/2017)... May 5, 2017 RAM Group ... a new breakthrough in biometric authentication based on ... mechanical properties to perform biometric authentication. These new sensors ... material created by Ram Group and its partners. This ... transportation, supply chains and security. Ram Group is ...
Breaking Biology News(10 mins):